IsoRay (NYSEAMERICAN:ISR) Stock Price Up 8.1%

IsoRay, Inc. (NYSEAMERICAN:ISR) rose 8.1% on Thursday . The stock traded as high as $0.42 and last traded at $0.40, approximately 4,700 shares changed hands during trading. A decline of 97% from the average daily volume of 153,379 shares. The stock had previously closed at $0.37.

Separately, Zacks Investment Research upgraded IsoRay from a “hold” rating to a “buy” rating and set a $0.50 target price on the stock in a report on Saturday, September 28th.

The business has a 50-day moving average of $0.34 and a two-hundred day moving average of $0.39.

IsoRay (NYSEAMERICAN:ISR) last released its earnings results on Tuesday, November 12th. The healthcare company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.01. The firm had revenue of $2.32 million for the quarter, compared to analyst estimates of $2.23 million.

An institutional investor recently raised its position in IsoRay stock. Vanguard Group Inc. raised its stake in shares of IsoRay, Inc. (NYSEAMERICAN:ISR) by 11.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,594,907 shares of the healthcare company’s stock after purchasing an additional 169,100 shares during the quarter. Vanguard Group Inc. owned 2.37% of IsoRay worth $654,000 as of its most recent filing with the Securities and Exchange Commission.

IsoRay Company Profile (NYSEAMERICAN:ISR)

IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.

Recommended Story: The benefits and drawbacks of dollar cost averaging

Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with's FREE daily email newsletter.